Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

June 8, 2020

Study Completion Date

June 8, 2020

Conditions
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Interventions
OTHER

No Intervention

This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.

Trial Locations (15)

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Hospital, Washington D.C.

27710

Duke University, Durham

30322

Emory University, Atlanta

33606

University of South Florida, Tampa

55455

University of Minnesota Masonic Children's Hospital, Minneapolis

90027

Children's Hospital of Los Angeles, Los Angeles

Kaiser Permanente, Los Angeles

92868

Children's Hospital of Orange County, Orange

94304

Stanford University, Palo Alto

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

06511

Yale University, New Haven

02115

Boston Children's Hospital, Boston

All Listed Sponsors
lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT03768817 - Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program | Biotech Hunter | Biotech Hunter